|Coordinatore||"BIOTECHNOLOGICKY USTAV - AV CR, V.V.I."
address: VIDENSKA 1083
|Nazionalità Coordinatore||Czech Republic [CZ]|
|Totale costo||100˙000 €|
|EC contributo||100˙000 €|
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
|Anno di inizio||2010|
|Periodo (anno-mese-giorno)||2010-11-01 - 2014-10-31|
"BIOTECHNOLOGICKY USTAV - AV CR, V.V.I."
address: VIDENSKA 1083
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Glutamate carboxypeptidase II (GCPII) is a membrane-bound metallopeptidase with a vast pharmacological potential. Given the intimate involvement of the enzyme in neurotransmission under normal physiological conditions, it is not surprising that GCPII-specific inhibitors are neuroprotective in multiple preclinical models of neurodegeneration. Additionally, the cancer-associated form of GCPII is exploited as a target for immunotherapy/imaging of prostate cancer as well as neovasculature of solid tumors. Despite of its utilization in (pre)clinical settings, the physiological function of GCPII in the latter tissues is unknown and the whole picture is further complicated by the existence of GCPIII, a close GCPII homolog. The main goals of this proposal focus on the identification and development of novel reagents, tools and techniques associated with the GCPII/GCPIII system that may help addressing questions pertaining to the fundamental (patho)physiological roles of GCPII/GCPIII. We will use information from X-ray structures of GCPII/GCPIII complexes to modify and improve characteristics of small-molecule ligands currently used in experimental models of prostate cancer. Secondly, will develop an activity assay based on fluorescence polarization that, in turn, will be exploited for the identification of novel inhibitor scaffolds targeting GCPII/GCPIII. The physicochemical properties of the lead-like compounds will be further optimized to develop isoform (GCPII vs. GCPIII) specific reagents. Such compounds are not available at present and their availability is crucial for dissecting potentially diverse physiological functions of GCPIII and GCPII with implications for GCPII/III associated pathologies. Lastly, we will try to gain insight into non-enzymatic (receptor-like) properties of GCPII by identifying physiological interaction partner(s) of the enzyme using a tandem affinity purification approach.'
Scientists have found numerous ligands of a membrane-bound protein implicated in an unusual array of pathologies from neurotoxicity to prostate cancer. The ligands will help unravel diverse functions and develop targeted therapies.
Dynamics of Confined Complex SuspensionsRead More
Precise test of Lepton Universalty with decays of the charged kaon at the NA62 experiment at CERNRead More
Deciphering mycobacterial subversion of early steps of adaptive immunity in vivo: A new approach to solve an old problemRead More